Objective
Allergic asthma is a chronic inflammatory disease of the airways and a worldwide problem. Dendritic cells (DC) have a key role in the development of this disease, making them interesting targets for therapy. Novel asthma therapies could involve interference with the development and relative abundance of functionally specialized lung DC subsets. Allergen exposure drastically changes airway DC subset distribution and preliminary experiments show effects on myeloid bone marrow progenitors. We hypothesize that DC precursor development, selection and differentiation choices are affected by allergen-induced airway inflammation and this might affect the outcome of the pulmonary immune response to allergens. Here, we aim to elucidate how asthma affects the distribution and differentiation capacity of DC progenitors/precursors at the cellular and the molecular level. In a novel house dust mite (HDM)-driven mouse asthma model, we will analyze HDM-induced changes in the distribution of bone marrow, circulating and lung-resident progenitors/precursors. In vitro development of progenitors/precursors isolated from HDM-exposed and control mice will be compared to identify imprinting effects on differentiation capacity. To find the mechanism by which asthma alters or imprints DC development from progenitors/precursors, HDM and asthma-associated cytokines will be added to in vitro DC differentiation cultures to evaluate their effects on development. The most promising candidates will be tested by analyzing DC development in HDM-exposed knockout mice and 50/50 mixed bone marrow chimeras. Moreover, gene expression profiles from progenitors/precursors isolated from HDM-exposed and control mice will be compared to identify new regulatory networks. Finally, findings will be validated in in vitro human DC differentiation cultures and human immune system mice. These data will help to define crucial DC development pathways during asthma that may be amenable to therapeutic intervention.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.
- medical and health sciences clinical medicine pneumology asthma
- medical and health sciences health sciences inflammatory diseases
- medical and health sciences basic medicine immunology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
FP7-PEOPLE-2012-IEF
See other projects for this call
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Coordinator
9052 ZWIJNAARDE - GENT
Belgium
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.